Donald W. Degolyer net worth and biography

Donald Degolyer Biography and Net Worth

Director of Emergent Biosolutions

Don DeGolyer has over 35 years of healthcare and corporate leadership experience. He was the Founder and Director of Vertice Pharma (a Warburg Pincus company), focused on specialty pharmaceuticals for U.S. institutional use, from 2015 until the sale in 2022. Prior to Vertice, he was Chief Operating Officer, Endo International, a Nasdaq listed specialty pharmaceutical company, from 2013-2015. Between 2009 and 2013, he served on the Executive Committee of Sandoz AG (a Novartis company), one of the largest global generic companies, as CEO, Sandoz Inc., a $3.5bn generic pharmaceuticals and biosimilars company where he was responsible for leading over 3,000 associates in North America.

Mr. DeGolyer started his career with Pfizer, Johnson & Johnson and Novartis in commercial roles of increasing responsibility. He served on the Board of HLS. Therapeutics (commercial stage CV/CNS company) and TYME Technologies (development stage cancer co), both publicly traded companies, where he was also Chairman of the Compensation Committees. He also serves on several non-profit boards including Make-a-Wish-NJ and The Strong Women Foundation.

Mr. DeGolyer has an MBA from Fairleigh Dickinson University and a Bachelor of Arts from University of Rochester.

What is Donald W. Degolyer's net worth?: The estimated net worth of Donald W. Degolyer is at least $1.09 million as of August 12th, 2025. Degolyer owns 137,659 shares of Emergent Biosolutions stock worth more than $1,094,389 as of March 27th. This net worth approximation does not reflect any other investments that Degolyer may own. Learn More about Donald W. Degolyer's net worth.
How do I contact Donald W. Degolyer?: The corporate mailing address for Degolyer and other Emergent Biosolutions executives is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. Emergent Biosolutions can also be reached via phone at (240) 631-3200 and via email at [email protected]. Learn More on Donald W. Degolyer's contact information.
Has Donald W. Degolyer been buying or selling shares of Emergent Biosolutions?: Donald W. Degolyer has not been actively trading shares of Emergent Biosolutions during the last ninety days. Most recently, Donald W. Degolyer sold 7,844 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $8.65, for a transaction totalling $67,850.60. Following the completion of the sale, the director now directly owns 137,659 shares of the company's stock, valued at $1,190,750.35. Learn More on Donald W. Degolyer's trading history.
Who are Emergent Biosolutions' active insiders?: Emergent Biosolutions' insider roster includes Donald Degolyer (Director), Neal Fowler (Director), Coleen Glessner (EVP), Keith Katkin (Director), Richard Lindahl (CFO), Ronald Richard (Director), and Kathryn Zoon (Director). Learn More on Emergent Biosolutions' active insiders.
Are insiders buying or selling shares of Emergent Biosolutions?: During the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 75,366 shares worth more than $749,349.10. The most recent insider tranaction occured on December, 5th when Director Ronald Richard sold 21,984 shares worth more than $263,148.48. Insiders at Emergent Biosolutions own 1.2% of the company. Learn More about insider trades at Emergent Biosolutions.
Information on this page was last updated on 12/5/2025.

Donald W. Degolyer Insider Trading History at Emergent Biosolutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/12/2025	Sell	7,844	$8.65	$67,850.60	137,659

Donald W. Degolyer Buying and Selling Activity at Emergent Biosolutions

Emergent Biosolutions Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $7.95

$7.90

$8.15

50 Day Range

MA: $10.05

$7.99

$12.23

2 Week Range

Now: $7.95

$4.02

$14.06

Volume

638,461 shs

Average Volume

965,982 shs

Market Capitalization

$410.54 million

P/E Ratio

9.46

Dividend Yield

N/A

Beta

2.41